Latest Stock Buy or Sell? Make More Informed Decisions!
Today, The Panic-Proof Portfolio (Stockchase Research) and Paul MacDonald commented about whether MRK-N, ANTM-N, HCA-N, ISRG-Q, SYK-N, HDIF-T, HHL-T, TMO-N, ABBV-N, BMY-N, UNH-N, PFE-N, MRNA-Q, LLY-N, NVO-N, VTRS-Q, RPRX-Q, DHT.UN-T, BMO-T, AAPL-Q, UPS-N, AEM-T, FITB-Q, BUD-N, GLW-N are stocks to buy or sell.
- Page 1/3
- Next Page
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly GLW is the maker of Gorilla Glass, vaccine vials, and glass products used in LED display and fiber optics. It operates in 15 countries. Recent earnings seem to demonstrate the continued ability to pass along rising costs to its customers, making it a good inflation hedge. And with next years earnings expected to be stronger, it supports a 13x earnings valuation, compared to peers at 28x. The dividend has been growing for 13 consecutive years and is expected to be a payout ratio of <45%, based on next year's earning outlook. The company has been using some cash reserves to buy back stock and retire debt, but there is plenty still left in the tank. We recommend a stop loss at $27, looking to achieve $46 -- upside potential over 30%. Yield 3.0% (Analysts’ price target is $46.10)
misc industrial products
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly Recently reported earnings support the ability of BUD to be able to pass along rising costs to consumers, making it a good inflation hedge. It continues to expand its product line beyond just its iconic beer and has established a strong brand affiliation with the NFL (whose league will begin again soon). Growth in next year's earnings are expected to value the company at 15x earnings compared to peers at 19x. It trades at just 1.4x book value. It has used prudently used some cash reserves to aggressively retire debt early. We recommend at stop loss at $46, looking to achieve $73 - upside potential of 33%. Yield 0.75% (Analysts’ price target is $73.00)
breweries
beverages
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly This regional bank is growing market share in key markets in the Southeast, West Coast and Chicago and is expanding its presence with an effective fintech platform strategy. Rising interest rates will help their bottom line going forward. It trades at 10x earnings and under 1.4x book value. It pays a good dividend, that has been growing for 11 consecutive years, and is backed by a payout ratio under 35% of cashflow. It has been aggressively buying back shares and retiring debt. We recommend a stop loss at $27, looking to achieve $49 -- upside over 35%. Yield 3.28% (Analysts’ price target is $49.29)
banks
Premium content
PAST TOP PICK
(A Top Pick Apr 12/22, Down 18.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AEM has triggered its stop at $67. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 9%, when combined with the previous top pick recommendation.
precious metals
Premium content
PAST TOP PICK
(A Top Pick Apr 12/22, Down 5.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with UPS has triggered its stop at $177. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 3%, when combined with the previous top pick recommendation.
Transportation
Premium content
PAST TOP PICK
(A Top Pick Apr 07/22, Down 11.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AAPL has triggered its stop at $152. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 2%, when combined with the previous top pick recommendation.
electrical
electronic
Premium content
PAST TOP PICK
(A Top Pick Apr 26/22, Down 5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BMO has triggered its stop at $132. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 5%, when combined with the previous top pick recommendation.
banks
COMMENT
Healthcare amid volatility. Challenging environment, to say the least. Macro uncertainty, inflation running hot, interest rate uncertainty. Relatively, healthcare is holding up quite well given the volatility we're seeing. But not all healthcare. Some areas, like smaller cap and higher growth, are more impacted.
COMMENT
Grey tsunami fueling bullish outlook? Absolutely. Healthcare is one of the very few areas of the market that's well positioned for the aging population dynamic. As people age, they spend exponentially more on their healthcare needs. There are non-cyclical drivers as well, like developing markets and technological innovation in medical devices, pharma, bio, and bio tech. The macro environment is very strong. Visibility across many sub-sectors is challenged with rising interest rates. Healthcare is known as a superior good, and so it has pricing power. We need it in up and down markets. Healthcare is where investors should be. Canada has few offerings. You should be looking for at least a market weight toward the sector, which is 13-15% globally.
COMMENT
Criteria for healthcare stocks. Dominant companies, proven ability to execute over economic cycles. Large cap with diversified product lineups. As you're reviewing and rebalancing your portfolio, you really want to be in quality companies. Robust financial metrics, reliability of earnings across economic cycles.
DON'T BUY
Too small for him, challenging environment. Management seems solid. Invests in biotech and pharma companies in exchange for a royalty. Drugs are coming off patent, so revenues will decline. Check out the payout ratio. He tracks RPRX in the US, which is 100x bigger with 25B market cap.
Trust, Savings and Loan
WEAK BUY
NVO vs. LLY Focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.
biotechnology
pharmaceutical
BUY
LLY vs. NVO NVO is focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.
biotechnology
pharmaceutical
